TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 110027

Group type: EXPERIMENTAL
Intervention: Disodium chromoglycate (DSCG) nasal spray (2%)
Number of subjects: 38

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 38
Study: 31112399

Group type: EXPERIMENTAL
Intervention: onabotulinumtoxinA (155-195 U)
Number of subjects: 1384

Group type: COMPARATOR
Intervention: placebo
Number of subjects: 1384
Study: 27466231

Group type: EXPERIMENTAL
Intervention: ABP 501
Number of subjects: 203

Group type: COMPARATOR
Intervention: Adalimumab (USA)
Number of subjects: 203

Group type: COMPARATOR
Intervention: Adalimumab (EU)
Number of subjects: 203
Study: 25445827

Group type: EXPERIMENTAL
Intervention: Telephone-based peer coaching for parents (median, 18 calls)
Number of subjects: 948

Group type: EXPERIMENTAL
Intervention: Telephone-based peer coaching for parents (median, 18 calls) in Medicaid subgroup
Number of subjects: 948
Study: 23709432

Group type: EXPERIMENTAL
Intervention: Nicorandil 12 mg in 100 mL of 0.9% saline administered intravenously for 30 minutes prior to coronary angiography
Number of subjects: 166

Group type: COMPARATOR
Intervention: Control group received saline only
Number of subjects: 166

Group type: EXPERIMENTAL
Intervention: Nicorandil group
Number of subjects: 166

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 166
Study: 21849080

Group type: EXPERIMENTAL
Intervention: 3-4 ml/kg BW/h 0.9% saline intravenously for 6 hours
Number of subjects: 1200

Group type: COMPARATOR
Intervention: Standard treatment consisting of unrestricted oral fluid intake
Number of subjects: 1200
Study: 20110017

Group type: EXPERIMENTAL
Intervention: Glimepiride 1-mg + Metformin 500-mg combination tablet (test)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Glimepiride 2-mg + Metformin 500-mg combination tablet (reference)
Number of subjects: 30
Study: 16882276

Group type: EXPERIMENTAL
Intervention: Pioglitazone (30-45 mg daily for 26 weeks)
Number of subjects: 54

Group type: COMPARATOR
Intervention: Pioglitazone withdrawal (after 26 weeks)
Number of subjects: 54
Study: 14742333

Group type: EXPERIMENTAL
Intervention: Senior anaesthetists (group A, >15 years experience)
Number of subjects: 300

Group type: COMPARATOR
Intervention: Junior anaesthetists (group B, >6 months but <1 year training)
Number of subjects: 300

Group type: EXPERIMENTAL
Intervention: Overall assessment of difficulty score
Number of subjects: 300
Study: 11598361

Group type: EXPERIMENTAL
Intervention: Transvaginal hydrolaparoscopy (THL)
Number of subjects: 43

Group type: COMPARATOR
Intervention: Chromolaparoscopy
Number of subjects: 43
Study: 9144049

Group type: EXPERIMENTAL
Intervention: Hapika Powerbrush
Number of subjects: 66

Group type: COMPARATOR
Intervention: Interplak ultra 10 tuft
Number of subjects: 66
Study: 8181411

Group type: EXPERIMENTAL
Intervention: Listening to self-selected music during the procedure
Number of subjects: 50

Group type: COMPARATOR
Intervention: Standard sigmoidoscopy protocol (Control)
Number of subjects: 50
Study: 3046984

Group type: EXPERIMENTAL
Intervention: 5 g of pectin
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: 10 g of pectin
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: 15 g of pectin
Number of subjects: 12
Study: 31395087

Group type: EXPERIMENTAL
Intervention: Incidence density ratio (IDR)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Rule of thumb for IDR
Number of subjects: 0
Study: 29505900

Group type: EXPERIMENTAL
Intervention: Paclitaxel (175 mg/m2) plus Carboplatin (AUC 5) every 3 weeks for four cycles (arm A)
Number of subjects: 402

Group type: COMPARATOR
Intervention: Oral Uracil-Tegafur (UFT) (250 mg/m2) daily for 2 years (arm B)
Number of subjects: 402
Study: 27289007

Group type: EXPERIMENTAL
Intervention: Calories-only labeling
Number of subjects: 643

Group type: EXPERIMENTAL
Intervention: Calories plus equivalent miles of walking labeling
Number of subjects: 643

Group type: COMPARATOR
Intervention: No information labeling
Number of subjects: 643
Study: 24374004

Group type: EXPERIMENTAL
Intervention: High Protein Diet (HPD)
Number of subjects: 76

Group type: COMPARATOR
Intervention: Standard Protein Diet (SPD)
Number of subjects: 76

Group type: EXPERIMENTAL
Intervention: Both diets
Number of subjects: 76
Study: 22657157

Group type: EXPERIMENTAL
Intervention: Methotrexate (MTX) 15 mg/m(2)/wk and prednisone 1 mg/kg/d (maximum 50 mg) for the first 3 months
Number of subjects: 65

Group type: EXPERIMENTAL
Intervention: Methotrexate (MTX)
Number of subjects: 65
Study: 20491606

Group type: EXPERIMENTAL
Intervention: Candesartan-based treatment
Number of subjects: 2049

Group type: COMPARATOR
Intervention: Non-ARB treatment
Number of subjects: 2049
Study: 18850395

Group type: EXPERIMENTAL
Intervention: Forceful persuasive messages advocating exercise activities
Number of subjects: 247

Group type: COMPARATOR
Intervention: Not applicable
Number of subjects: 247
Study: 15006977

Group type: EXPERIMENTAL
Intervention: STRT (stress testing)
Number of subjects: 292

Group type: EXPERIMENTAL
Intervention: Provocable ischemia (positive STRT results)
Number of subjects: 292

Group type: EXPERIMENTAL
Intervention: No STRT due to unstable angina
Number of subjects: 292
Study: 11691515

Group type: EXPERIMENTAL
Intervention: Quinapril 40 mg
Number of subjects: 8

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 8

Group type: COMPARATOR
Intervention: Losartan 50 mg
Number of subjects: 8
Study: 9176870

Group type: EXPERIMENTAL
Intervention: Selenium supplementation (Sel, N = 12)
Number of subjects: 24

Group type: COMPARATOR
Intervention: Placebo (Pla, N = 12)
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Both groups (Sel and Pla)
Number of subjects: 24
Study: 7942642

Group type: EXPERIMENTAL
Intervention: Advocacy services from an advocate, 4 to 6 hours per week for the first 10 weeks postshelter
Number of subjects: 141

Group type: COMPARATOR
Intervention: No advocacy services (Control group)
Number of subjects: 141
Study: 2906457

Group type: EXPERIMENTAL
Intervention: roxatidine acetate 75 mg
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: roxatidine acetate 150 mg
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: roxatidine acetate 300 mg
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: roxatidine acetate 600 mg
Number of subjects: 10

Group type: COMPARATOR
Intervention: placebo
Number of subjects: 10
Study: 29734096

Group type: EXPERIMENTAL
Intervention: Antidepressants (bupropion, paroxetine) as adjuncts to mood stabilizers
Number of subjects: 320

Group type: COMPARATOR
Intervention: Placebo as adjunct to mood stabilizers
Number of subjects: 320
Study: 27276373

Group type: EXPERIMENTAL
Intervention: CGT with PLA
Number of subjects: 395

Group type: EXPERIMENTAL
Intervention: CGT with CIT
Number of subjects: 395

Group type: COMPARATOR
Intervention: CIT
Number of subjects: 395

Group type: EXPERIMENTAL
Intervention: CGT
Number of subjects: 395
Study: 25199409

Group type: EXPERIMENTAL
Intervention: Diminazene diaceturate (DA) treatment
Number of subjects: 3084

Group type: EXPERIMENTAL
Intervention: Graded RAP (25%, 50%, and 75% of village herd sprayed)
Number of subjects: 3084

Group type: COMPARATOR
Intervention: Control group (no RAP)
Number of subjects: 3084
Study: 24319686

Group type: EXPERIMENTAL
Intervention: Nilvadipine (oral administration)
Number of subjects: 41

Group type: COMPARATOR
Intervention: Control group (no specific intervention mentioned)
Number of subjects: 41
Study: 20958228

Group type: EXPERIMENTAL
Intervention: L-arginine (L-Arg) supplementation
Number of subjects: 80

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 80
Study: 18509120

Group type: EXPERIMENTAL
Intervention: Subcutaneous methylnaltrexone (0.15 mg/kg)
Number of subjects: 133

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 133
Study: 17191025

Group type: EXPERIMENTAL
Intervention: Chickpea-supplemented diet
Number of subjects: 47

Group type: COMPARATOR
Intervention: Wheat-supplemented diet
Number of subjects: 47
Study: 12709698

Group type: EXPERIMENTAL
Intervention: Endoscopic mucosal resection with immediate bleeding
Number of subjects: 477

Group type: COMPARATOR
Intervention: Endoscopic mucosal resection without immediate bleeding
Number of subjects: 477
Study: 11232191

Group type: EXPERIMENTAL
Intervention: Specific vaccines for hepatitis A and B
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Aggressive combination therapy for chronic hepatitis B and C
Number of subjects: 0
Study: 9081951

Group type: EXPERIMENTAL
Intervention: 0.4 ml/kg (1:200,000) epinephrine combined with 0.25% bupivacaine (n = 33)
Number of subjects: 103

Group type: EXPERIMENTAL
Intervention: 1:200,000 epinephrine (n = 36)
Number of subjects: 103

Group type: COMPARATOR
Intervention: 0.9% NaCl (control group, n = 34)
Number of subjects: 103

Group type: EXPERIMENTAL
Intervention: Postoperative pain assessment methods
Number of subjects: 103
Study: 1313098

Group type: EXPERIMENTAL
Intervention: Acyclovir (800 mg orally four times daily for 5 days)
Number of subjects: 62

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 62
Study: 2860992

Group type: EXPERIMENTAL
Intervention: Atenolol (Tenormin, 100 mg) given twice daily for 6 weeks
Number of subjects: 8

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 8
Study: 30848938

Group type: EXPERIMENTAL
Intervention: 4-week multimodal rehabilitation program (12 intervention sessions and daily home ankle strengthening and stretching)
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: 4-week multimodal rehabilitation program
Number of subjects: 20
Study: 29547070

Group type: EXPERIMENTAL
Intervention: Combination HIV prevention intervention
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Collective agency among sex workers
Number of subjects: 24
Study: 26845264

Group type: EXPERIMENTAL
Intervention: Lithium + adjunctive personalized treatment (APT)
Number of subjects: 482

Group type: EXPERIMENTAL
Intervention: Quetiapine + adjunctive personalized treatment (APT)
Number of subjects: 482

Group type: EXPERIMENTAL
Intervention: Lithium
Number of subjects: 482

Group type: EXPERIMENTAL
Intervention: Quetiapine
Number of subjects: 482
Study: 24158407

Group type: EXPERIMENTAL
Intervention: Cold Water Immersion (CWI)
Number of subjects: 14

Group type: COMPARATOR
Intervention: Passive Recovery (PAS)
Number of subjects: 14
Study: 22818869

Group type: EXPERIMENTAL
Intervention: Vitamin B(6) (50 mg/d)
Number of subjects: 85

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 85

Group type: EXPERIMENTAL
Intervention: Lysine (1 g/d)
Number of subjects: 85

Group type: EXPERIMENTAL
Intervention: Carnitine (1 g/d)
Number of subjects: 85

Group type: EXPERIMENTAL
Intervention: Lysine (1 g/d) + Vitamin B(6) (50 mg/d)
Number of subjects: 85
Study: 20631020

Group type: EXPERIMENTAL
Intervention: Vitamin D supplementation (150,000 IU ergocalciferol, 4 doses over 1 year)
Number of subjects: 69

Group type: COMPARATOR
Intervention: Control group (no vitamin D supplementation)
Number of subjects: 69

Group type: EXPERIMENTAL
Intervention: Vitamin D supplementation
Number of subjects: 69
Study: 17908660

Group type: EXPERIMENTAL
Intervention: PRONE (n = 11)
Number of subjects: 22

Group type: COMPARATOR
Intervention: SUPINE (n = 11)
Number of subjects: 22
Study: 12574809

Group type: EXPERIMENTAL
Intervention: Melagatran followed by oral ximelagatran (3 mg subcutaneous melagatran started 4-12 h postoperatively, followed by 24 mg oral ximelagatran twice-daily for 8 to 11 days)
Number of subjects: 2788

Group type: COMPARATOR
Intervention: Enoxaparin (40 mg subcutaneous enoxaparin once-daily, started 12 h preoperatively)
Number of subjects: 2788

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 2788
Study: 10711583

Group type: EXPERIMENTAL
Intervention: Cognitive-behavioral stress management (CBSM)
Number of subjects: 65

Group type: COMPARATOR
Intervention: Wait-list control group
Number of subjects: 65
Study: 8941404

Group type: EXPERIMENTAL
Intervention: Paclitaxel/cisplatin
Number of subjects: 73

Group type: COMPARATOR
Intervention: Teniposide/cisplatin
Number of subjects: 73
Study: 1587940

Group type: EXPERIMENTAL
Intervention: 1% solution of povidon iodine (Betadine)
Number of subjects: 334

Group type: COMPARATOR
Intervention: Normal saline
Number of subjects: 334
Study: 3907910

Group type: EXPERIMENTAL
Intervention: Verapamil 20 mg intravenously
Number of subjects: 20

Group type: COMPARATOR
Intervention: Control group (no verapamil)
Number of subjects: 20
Study: 30773140

Group type: EXPERIMENTAL
Intervention: Lipid-based nutritional supplement with additional micronutrients
Number of subjects: 875

Group type: COMPARATOR
Intervention: Lipid-based nutritional supplement without additional micronutrients
Number of subjects: 875

Group type: COMPARATOR
Intervention: Iron-folate (standard care)
Number of subjects: 875

Group type: COMPARATOR
Intervention: Multiple micronutrients
Number of subjects: 875

Group type: COMPARATOR
Intervention: Protein energy
Number of subjects: 875

Group type: COMPARATOR
Intervention: Protein energy + multiple micronutrients
Number of subjects: 875
Study: 28633996

Group type: EXPERIMENTAL
Intervention: Carbidopa/levodopa (DOPA)
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: d-amphetamine (AMPH)
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: methylphenidate (MEPH)
Number of subjects: 10

Group type: COMPARATOR
Intervention: Placebo (PLAC)
Number of subjects: 10
Study: 26116695

Group type: EXPERIMENTAL
Intervention: Exenatide (5 μg)
Number of subjects: 15

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 15
Study: 23800140

Group type: EXPERIMENTAL
Intervention: qHBsAg index
Number of subjects: 197

Group type: EXPERIMENTAL
Intervention: GqHBsR
Number of subjects: 197

Group type: EXPERIMENTAL
Intervention: FIB-4
Number of subjects: 197

Group type: EXPERIMENTAL
Intervention: aspartate aminotransferase to platelet ratio index
Number of subjects: 197
Study: 21335058

Group type: EXPERIMENTAL
Intervention: Occipital TMS during non-REM sleep
Number of subjects: 0

Group type: COMPARATOR
Intervention: Occipital TMS during wakefulness
Number of subjects: 0
Study: 20003665

Group type: EXPERIMENTAL
Intervention: Cranberry drink (500 ml twice per day)
Number of subjects: 12

Group type: COMPARATOR
Intervention: Water
Number of subjects: 12
Study: 17013602

Group type: EXPERIMENTAL
Intervention: Hydroxyapatite porous coating
Number of subjects: 100

Group type: COMPARATOR
Intervention: Control group (no coating)
Number of subjects: 100
Study: 14520337

Group type: EXPERIMENTAL
Intervention: Clozapine
Number of subjects: 6

Group type: COMPARATOR
Intervention: Haloperidol
Number of subjects: 6
Study: 11307640

Group type: EXPERIMENTAL
Intervention: Bupivacaine
Number of subjects: 0

Group type: COMPARATOR
Intervention: Lidocaine
Number of subjects: 0
Study: 8769051

Group type: EXPERIMENTAL
Intervention: GR3219 80 mg twice daily
Number of subjects: 59

Group type: COMPARATOR
Intervention: Aspirin 300 mg daily
Number of subjects: 59
Study: 1573046

Group type: EXPERIMENTAL
Intervention: Alprazolam 2 mg
Number of subjects: 94

Group type: EXPERIMENTAL
Intervention: Alprazolam 6 mg
Number of subjects: 94

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 94
Study: 3881905

Group type: EXPERIMENTAL
Intervention: Nifedipine in cold hyperkalemic cardioplegic solution
Number of subjects: 0

Group type: COMPARATOR
Intervention: Sodium nitroprusside
Number of subjects: 0
Study: 31518155

Group type: EXPERIMENTAL
Intervention: Operative treatment
Number of subjects: 127

Group type: COMPARATOR
Intervention: Nonoperative treatment
Number of subjects: 127
Study: 29368365

Group type: EXPERIMENTAL
Intervention: Phlorotannin supplement (500 mg/day)
Number of subjects: 24
Study: 26850983

Group type: EXPERIMENTAL
Intervention: Oral misoprostol (50 μg every 4 hours)
Number of subjects: 1859

Group type: COMPARATOR
Intervention: Foley catheter (30 mL transcervical)
Number of subjects: 1859

Group type: EXPERIMENTAL
Intervention: Oral misoprostol
Number of subjects: 1859

Group type: COMPARATOR
Intervention: Foley catheter
Number of subjects: 1859
Study: 24550378

Group type: EXPERIMENTAL
Intervention: Caspofungin prophylaxis
Number of subjects: 222

Group type: COMPARATOR
Intervention: Placebo prophylaxis
Number of subjects: 222

Group type: EXPERIMENTAL
Intervention: Caspofungin preemptive therapy
Number of subjects: 222

Group type: COMPARATOR
Intervention: Placebo preemptive therapy
Number of subjects: 222
Study: 22099607

Group type: EXPERIMENTAL
Intervention: Selective serotonin reuptake inhibitors (escitalopram)
Number of subjects: 5

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 5
Study: 20819537

Group type: EXPERIMENTAL
Intervention: Nifekalant hydrochloride (NIF) administered continuously for at least 12 hours (group L)
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: Nifekalant hydrochloride (NIF) administered for 1 hour (group S)
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: Nifekalant hydrochloride (NIF) (both groups)
Number of subjects: 16
Study: 18424479

Group type: COMPARATOR
Intervention: M‐GA (mitoxantrone followed by glatiramer acetate)
Number of subjects: 40

Group type: COMPARATOR
Intervention: GA (glatiramer acetate alone)
Number of subjects: 40
Study: 16409566

Group type: EXPERIMENTAL
Intervention: Irbesartan, 300 mg
Number of subjects: 30

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 30
Study: 14978984

Group type: EXPERIMENTAL
Intervention: Ranitidine 50 mg (intravenous) 8 hourly
Number of subjects: 52

Group type: EXPERIMENTAL
Intervention: Sucralfate 1 g 8 hourly through a Ryle's tube
Number of subjects: 52

Group type: COMPARATOR
Intervention: Control group (no drug)
Number of subjects: 52
Study: 11201591

Group type: EXPERIMENTAL
Intervention: Dobutamine stress echocardiography
Number of subjects: 200

Group type: EXPERIMENTAL
Intervention: Dipyridamole thallium scintigraphy
Number of subjects: 200

Group type: EXPERIMENTAL
Intervention: Clinical suspicion of coronary artery disease
Number of subjects: 200
Study: 8698278

Group type: EXPERIMENTAL
Intervention: Moderate/Large plaque (n = 96)
Number of subjects: 181

Group type: EXPERIMENTAL
Intervention: Maximum intima-media thickness of the femoral artery
Number of subjects: 181

Group type: EXPERIMENTAL
Intervention: Clinical atherosclerosis
Number of subjects: 181

Group type: EXPERIMENTAL
Intervention: Fibrinogen, von Willebrand factor and thrombin/antithrombin complex
Number of subjects: 181
Study: 1538036

Group type: EXPERIMENTAL
Intervention: 3-wheeled walker
Number of subjects: 15

Group type: COMPARATOR
Intervention: 2-wheeled walker
Number of subjects: 15
Study: 31747864

Group type: EXPERIMENTAL
Intervention: Remote Ischemic Conditioning (RIC) - four 5-minute cycles
Number of subjects: 60

Group type: COMPARATOR
Intervention: Sham treatment
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Remote Ischemic Conditioning (RIC)
Number of subjects: 60
Study: 28520861

Group type: EXPERIMENTAL
Intervention: Percutaneous coronary intervention in France
Number of subjects: 1800

Group type: EXPERIMENTAL
Intervention: Percutaneous coronary intervention in Hungary
Number of subjects: 1800

Group type: EXPERIMENTAL
Intervention: Coronary artery bypass grafting in the UK
Number of subjects: 1800

Group type: COMPARATOR
Intervention: Blood cardioplegia usage
Number of subjects: 1800

Group type: COMPARATOR
Intervention: Bilateral internal mammary artery usage
Number of subjects: 1800

Group type: COMPARATOR
Intervention: Off-pump procedures
Number of subjects: 1800

Group type: COMPARATOR
Intervention: Implanted stents in percutaneous coronary intervention
Number of subjects: 1800

Group type: COMPARATOR
Intervention: Total stent length in percutaneous coronary intervention
Number of subjects: 1800

Group type: COMPARATOR
Intervention: Post-coronary artery bypass grafting medication - Acetylsalicylic acid
Number of subjects: 1800

Group type: COMPARATOR
Intervention: Post-coronary artery bypass grafting medication - Thienopyridine
Number of subjects: 1800

Group type: COMPARATOR
Intervention: Post-coronary artery bypass grafting medication - Statins
Number of subjects: 1800
Study: 25769902

Group type: EXPERIMENTAL
Intervention: Tropomyosin and sarcoplasmic calcium-binding proteins
Number of subjects: 86

Group type: EXPERIMENTAL
Intervention: Sarcoplasmic calcium-binding protein positive test
Number of subjects: 86

Group type: COMPARATOR
Intervention: Arginine kinase and hemocyanin
Number of subjects: 86

Group type: EXPERIMENTAL
Intervention: Myosin light chain testing
Number of subjects: 86

Group type: EXPERIMENTAL
Intervention: Detection of IgE to allergens and some of their epitopes
Number of subjects: 86
Study: 23698545

Group type: EXPERIMENTAL
Intervention: Dexmedetomidine (0.5 μg/kg)
Number of subjects: 92

Group type: COMPARATOR
Intervention: Saline (Control)
Number of subjects: 92
Study: 21301783

Group type: EXPERIMENTAL
Intervention: 5 μg/kg methionyl human granulocyte colony-stimulating factor (r-metHuG-CSF, filgrastim)
Number of subjects: 78
Study: 21226428

Group type: EXPERIMENTAL
Intervention: 7.5 mg (1.5 ml) hyperbaric levobupivacaine 0.5%
Number of subjects: 60

Group type: COMPARATOR
Intervention: 7.5 mg (4 ml) hypobaric levobupivacaine 0.1875%
Number of subjects: 60
Study: 17381974

Group type: EXPERIMENTAL
Intervention: High unsalted cashew nut diet
Number of subjects: 64

Group type: COMPARATOR
Intervention: Control diet (no nuts)
Number of subjects: 64

Group type: EXPERIMENTAL
Intervention: High walnut diet
Number of subjects: 64
Study: 15705722

Group type: EXPERIMENTAL
Intervention: BREx group (resistive exercise)
Number of subjects: 18

Group type: COMPARATOR
Intervention: BR group (bed rest only)
Number of subjects: 18
Study: 12913399

Group type: EXPERIMENTAL
Intervention: abciximab/rPA (n = 5)
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: tirofiban/TNK‐tPA (n = 5)
Number of subjects: 15

Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 15
Study: 9481529

Group type: EXPERIMENTAL
Intervention: 1000 mg elemental phosphate for one week; sodium acid phosphate tablets (500 mg elemental phosphorus) given with meals
Number of subjects: 22

Group type: EXPERIMENTAL
Intervention: 1500 mg elemental phosphate for one week; sodium acid phosphate tablets (500 mg elemental phosphorus) given with meals
Number of subjects: 22
Study: 8570043

Group type: EXPERIMENTAL
Intervention: Iodixanol 150 mgI/ml
Number of subjects: 86

Group type: COMPARATOR
Intervention: Iohexol 140 mgI/ml
Number of subjects: 86
Study: 2096212

Group type: EXPERIMENTAL
Intervention: Nisoldipine 10 mg orally twice daily for 3.5 days
Number of subjects: 24
Study: 81925

Group type: EXPERIMENTAL
Intervention: Propranolol 0.1 mg/kg intravenously followed by 320 mg orally over 27 h
Number of subjects: 20

Group type: COMPARATOR
Intervention: Control group (23 subjects)
Number of subjects: 20
Study: 31940039

Group type: EXPERIMENTAL
Intervention: Baseline PSA level of 0.49 ng/mL or less
Number of subjects: 10968

Group type: EXPERIMENTAL
Intervention: Baseline PSA level of 0.50-0.99 ng/mL
Number of subjects: 10968

Group type: EXPERIMENTAL
Intervention: Baseline PSA level of 1.00-1.99 ng/mL
Number of subjects: 10968

Group type: EXPERIMENTAL
Intervention: Baseline PSA level of 2.00-2.99 ng/mL
Number of subjects: 10968

Group type: EXPERIMENTAL
Intervention: Baseline PSA level of 3.00-3.99 ng/mL
Number of subjects: 10968

Group type: EXPERIMENTAL
Intervention: Baseline PSA level of 4.00 ng/mL and greater
Number of subjects: 10968

Group type: EXPERIMENTAL
Intervention: Baseline PSA level of 2.00 ng/mL or higher
Number of subjects: 10968